Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing’s syndrome.The setback cast doubt on CORT’s pipeline strength and triggered a sharp re-evaluation by analysts. It underscores the market’s sensitivity to regulatory developments…
Logan Mohtashami, a senior HousingWire analyst, believes mortgage rate stability – not rate cuts – will be the key…
On December 1st, famed investor Jim Cramer looked into the camera on CNBC’s Mad Money and made a provocative…
Analysts increasingly believe Microsoft could reach a $5 trillion market valuation in early 2026.The analysis is driven by accelerating…
China’s economy closed the year with a modest improvement in momentum, as official data showed factory activity expanding in…
Asian markets closed out the year on a subdued note amid thin holiday trading, capping a year of strong…
The IBEX 35 Index had a great performance in 2025 and was one of the best-performing global benchmarks. It…
India has decided to extend its safeguard duty on certain steel imports, underlining the government’s continued push to protect…
The FTSE 100 Index jumped by nearly 22% this year, confirming a strong bull run that started in March…